News

Should You Buy Eli Lilly Stock Before June 22?
Eli Lilly will be presenting data from studies on multiple GLP-1 drugs later this month. Eli Lilly (NYSE: LLY) stock hasn't ...
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...
Devdiscourse18h
Real-World Weight-Loss Results vs. Clinical Trials: The Reality of Obesity Medications
A new study shows weight-loss drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, yield lower weight reductions in ...
Health Rounds: Patients drop fewer pounds with weight-loss drugs in real world than in trials
By Nancy Lapid (Reuters) -People who take weight-loss drugs hoping to achieve the impressive results observed in large ...
Asianet Newsable on MSN19h
Hims & Hers Stock Falls After Eli Lilly Rules Out Telehealth Tie-Up: Citi Calls It Aggressive Stance, Retail Turns Bearish
If Hims were to align with Lilly, Citi warned, it would signal the company has "thrown in the towel" on compounded medications.
Zacks.com on MSN13h
NVO Stock Gains After Parvus Asset Management Builds Stake
Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.
UNILAD17h
Doctors explain exactly what could happen to your body if you try 'golden dose' hack for Ozempic and Mounjaro that could be fatal
Doctors have explained what the 'golden dosing' trend does to your body as Ozempic and Mounjaro rise in popularity for weight ...
Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today released the Asia Pacific (APAC) findings from its 10th annual Future Health Index (FHI) report, the largest global ...